Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (61-70 of 131) with videos related to

Pageof 14
Sort By:
Ultrasound in Medicine & Biology|September 4, 2018
In Vivo Viscoelastic Response (VisR) Ultrasound for Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys with and without Duchenne Muscular DystrophyChristopher J Moore, Melissa C Caughey, Diane O Meyer, et al.
Frontiers in Public Health|September 28, 2023
The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challengesTom Hughes, James F Howard, Nicholas J Silvestri, et al.
European Journal of Neurology|October 7, 2024
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravisAli A Habib, Michael Benatar, Tuan Vu, et al.
NEJM Evidence|February 6, 2024
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Neurology|November 24, 2020
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label ExtensionRenato Mantegazza, Gil I Wolfe, Srikanth Muppidi, et al.
Neurology and Therapy|June 23, 2023
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Muscle & Nerve|June 23, 2025
Pain Experiences and Prescription Pain Medications Among People With Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research NetworkJonathan Suhl, Kristin M Conway, Shiny Thomas, et al.
Expert Opinion on Investigational Drugs|April 1, 2021
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia GravisJames F Howard, John Vissing, Nils E Gilhus, et al.
Journal of Neurology|February 24, 2024
Improvement of fatigue in generalised myasthenia gravis with zilucoplanMichael D Weiss, Miriam Freimer, M Isabel Leite, et al.
Journal of Neuroimmunology|October 15, 2018
Circulating microRNA plasma profile in MuSK+ myasthenia gravisLiis Sabre, Jeffrey T Guptill, Melissa Russo, et al.
Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
Ultrasound in Medicine & Biology|September 4, 2018
In Vivo Viscoelastic Response (VisR) Ultrasound for Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys with and without Duchenne Muscular DystrophyChristopher J Moore, Melissa C Caughey, Diane O Meyer, et al.
Frontiers in Public Health|September 28, 2023
The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challengesTom Hughes, James F Howard, Nicholas J Silvestri, et al.
European Journal of Neurology|October 7, 2024
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravisAli A Habib, Michael Benatar, Tuan Vu, et al.
NEJM Evidence|February 6, 2024
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Neurology|November 24, 2020
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label ExtensionRenato Mantegazza, Gil I Wolfe, Srikanth Muppidi, et al.
Neurology and Therapy|June 23, 2023
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Muscle & Nerve|June 23, 2025
Pain Experiences and Prescription Pain Medications Among People With Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research NetworkJonathan Suhl, Kristin M Conway, Shiny Thomas, et al.
Expert Opinion on Investigational Drugs|April 1, 2021
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia GravisJames F Howard, John Vissing, Nils E Gilhus, et al.
Journal of Neurology|February 24, 2024
Improvement of fatigue in generalised myasthenia gravis with zilucoplanMichael D Weiss, Miriam Freimer, M Isabel Leite, et al.
Journal of Neuroimmunology|October 15, 2018
Circulating microRNA plasma profile in MuSK+ myasthenia gravisLiis Sabre, Jeffrey T Guptill, Melissa Russo, et al.
Pageof 14